Skip to content
FIND A HEALTH VALLEY ACTOR

New Gene Therapy Laboratory at the Biofactory Competence Center (BCC) in Fribourg

BCC Fribourg

A jewel for biopharmaceutical education and research   The Biofactory Competence Center (BCC) in Freiburg inaugurated its new gene therapy laboratory on Wednesday 7 September 2022. This state-of-the-art facility will meet the growing needs of the Swiss biopharmaceutical industry in terms of the training of specialised staff and the production of drugs. Thanks to a…

Read More

Forum des 100 – Le Temps

Forum des 100

Two BioAlps experts nominated   Two Life Sciences experts, Dominique Truchot-Cardot and Alexandre Pauchard, are among the 100 personalities of the year in French-speaking Switzerland and have been selected by Le Temps Magazine for the Forum des 100. The conference will take place on 11 October 2022 at the Swiss Tech Convention Center.   Dominique…

Read More

Biopôle Vanguard Accelerator

Vanguard Accelerator Biopôle

This six-month programme, supported by Biopôle SA and its partners, helps health-oriented projects to grow. The Vanguard Accelerator is a free six-month programme, run by Biopôle SA and its partners, to help digital-health-oriented projects supercharge their innovation and take their business strategy to the next level. This immersive programme is a unique opportunity for early-stage…

Read More

CHUV, HUG and Inserm help Down syndrome patients to get better

Chuv Trisomie 21

The injection of the hormone GnRH improved the cognitive functions of several Down syndrome patients   An Inserm team within the Lille neuroscience & cognition laboratory (Inserm/University of Lille/CHU of Lille), the Centre Hospitalier Universitaire Vaudois (CHUV) and The Hôpitaux Universitaires de Genève (HUG) have collaborated to test the efficacy of a therapy based on…

Read More

Parkinson’s Disease: AC Immune Receives a Grant from The Michael J. Fox Foundation

AC Immune MJFOX

A new USD 0.5 million grant brings up to USD 3.7 million the total amount The Michael J. Fox Foundation awarded the Swiss company. AC Immune SA, a Lausanne-based clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded the Company a new…

Read More

A wearable tissue health monitor

Sensawear

Sensawear wins a CHF 150,000 Venture Kick grant to develop its wearable tissue health monitor   Sensawear has developed the world’s first truly wearable, textile-based, tissue oxygenation monitoring sensor using trusted, proven, non-invasive near-infrared spectroscopy. Specially integrated fiber optics will give users real-time feedback on deep tissue oxygen saturation without adding pressure against the skin.…

Read More

DayOne Tech Accelerator presents its first cohort

Day One Jura

The DayOne Tech Accelerator in the Canton of Jura has just announced its winners. Three Medtech startups are starting a 12-month programme. Experts will help to push them to a higher level.   CNS Therapy (Zug): Drug-free pain treatment The company has developed the ability to treat chronic pain patients using neuromodulation and behavioral therapy.…

Read More

AC BioScience closes a 4th seed-round of CHF 2.5 million

AC Bioscience

AC BioScience, a Biopôle-based clinical-stage biotech company pioneering the development of novel therapies in immuno-oncology and tumour vascular normalization, announces a fourth Seed Round for CHF 2.5 million.   Founded by Andreas Schlaepfer and Professor Christian Auclair, AC BioSciences develops personalized molecular therapies designed to optimize efficiency or bolster the therapeutic benefit for particular groups…

Read More

Alcon buys Aerial Pharmaceutics for $770 million

Alcon

Ophthalmic devices and Geneva-based Alcon has reached an agreement to acquire North Carolina-based Aerie Pharmaceuticals for $770 million (743.1 million francs).   The transaction will strengthen the former Novartis subsidiary’s position in the fields of glaucoma and dry eye. Alcon will acquire Rocklatan (netarsudil and latanoproste) and Rhopressa (netarsudil), which are approved for the reduction…

Read More

Abionic’s test diagnoses sepsis 3 days before the standards methods

Abionic

Abionic’s test identifies in 5 minutes the earliest signs of sepsis 3 days before the standard of care. The technology just received a European IVDR certification for its in-vitro diagnostics.   Abionic SA, a developer of disruptive nanotechnology-based diagnostic solutions, announces that its Pancreatic Stone Protein (PSP) test on the abioSCOPE® has been certified by…

Read More